Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Riely

Showing results (1-10 of 293) with videos related to

Pageof 30
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 3, 2008
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutationsGregory J Riely
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011
Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitorsGregory J Riely
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutationsGregory J Riely
Oncology (Williston Park, N.Y.)|March 2, 2010
Lung cancer in 'Never-smokers': molecular factors trump risk factorsGregory J Riely
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerGregory J Riely
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 23, 2010
Induction therapy for locally advanced thymomaGregory J Riely, James Huang
The Journal of Molecular Diagnostics : JMD|October 4, 2008
KRAS mutations: an old oncogene becomes a new predictive biomarkerGregory J Riely, Marc Ladanyi
Cancer Biology & Therapy|November 19, 2005
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?Gregory J Riely, William Pao
The European Respiratory Journal|May 3, 2014
Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?Gregory J Riely, William D Travis
The Lancet. Oncology|October 20, 2012
Who should receive EGFR tyrosine-kinase inhibitors?Helena A Yu, Gregory J Riely
Pageof 30

Showing results (1-10 of 293) with videos related to

Sort By:
Pageof 30
Lung Cancer (Amsterdam, Netherlands)|June 3, 2008
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutationsGregory J Riely
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011
Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitorsGregory J Riely
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutationsGregory J Riely
Oncology (Williston Park, N.Y.)|March 2, 2010
Lung cancer in 'Never-smokers': molecular factors trump risk factorsGregory J Riely
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerGregory J Riely
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 23, 2010
Induction therapy for locally advanced thymomaGregory J Riely, James Huang
The Journal of Molecular Diagnostics : JMD|October 4, 2008
KRAS mutations: an old oncogene becomes a new predictive biomarkerGregory J Riely, Marc Ladanyi
Cancer Biology & Therapy|November 19, 2005
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?Gregory J Riely, William Pao
The European Respiratory Journal|May 3, 2014
Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?Gregory J Riely, William D Travis
The Lancet. Oncology|October 20, 2012
Who should receive EGFR tyrosine-kinase inhibitors?Helena A Yu, Gregory J Riely
Pageof 30